论文信息 - Experience with Systemic Bevacizumab in Advanced Juvenile Recurrent Respiratory Papillomatosis - 字舞流文

Experience with Systemic Bevacizumab in Advanced Juvenile Recurrent Respiratory Papillomatosis

A. Bhalla | J. Kumari | Arvind Kumar | Raj Kumar | K. Jat | S. K. Kabra | K. Aggarwal | Rakesh Kumar

[1] C. Derkay,et al. Update on Recurrent Respiratory Papillomatosis. , 2019, Otolaryngologic clinics of North America.

[2] C. Carnevale,et al. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children , 2018, The Laryngoscope.

[3] J. Hoekstra-Weebers,et al. Quality of life of patients with recurrent respiratory papillomatosis , 2017, The Laryngoscope.

[4] K. Zur,et al. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child , 2017, The Laryngoscope.

[5] K. Zur,et al. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey , 2017, The Laryngoscope.

[6] C. Rudack,et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis , 2014, Oncology letters.

[7] G. Scadding,et al. RECURRENT RESPIRATORY PAPILLOMATOSIS , 1988, The Lancet.

[8] J. Folkman,et al. Role of Vascular Endothelial Growth Factor–A in Recurrent Respiratory Papillomatosis , 2005, The Annals of otology, rhinology, and laryngology.

[9] B. Leventhal,et al. Recurrent respiratory papillomatosis. , 1985, Journal of biological response modifiers.